Download PDF
Thromb Haemost 1984; 51(03): 398-402
DOI: 10.1055/s-0038-1661111
Original Article
Schattauer GmbH Stuttgart

Anticoagulant Properties of Purified X-Like Fragments of Human Fibrinogen Produced by Degradation with Leukocyte Elastase

Lydi Sterrenberg
The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
Gert Jan van Liempt
The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
Willem Nieuwenhuizen
The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
Jo Hermans
1   The Department of Medical Statistics, State University of Leiden, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 16 January 1984

Accepted 02 May 1984

Publication Date:
19 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The anticoagulant properties of fibrinogen digestion products change with stage of digestion. On digestion with leukocyte elastase, in the presence of calcium ions, the anticoagulant potency of fibrinogen digests first increases, then decreases sharply, and in late stages increases again. This is different from plasmin digestion where only an increase in anticoagulant activity is seen followed by a slow decrease.

From SDS-gel electrophoresis it appears that both the early rise and the decrease in anticoagulant activity are associated with the stage of elastase-produced X-like fragments. This is confirmed with pure fragments: X-like fragments (purified from elastase digests of fibrinogen of different stages by ammonium sulphate precipitation and ion-exchange chromatography) give an increase and decrease in anticlotting activity which correlates very well with that of the potency of the digest from which they are purified. As expected, and in contrast with (late) plasmic X- fragments, late elastase X-like fragments have a low anticoagulant potency. The molecular basis for the gain and loss in anticoagulant activity going from early to late X-like fragments is obscure. Immunological tests, calcium-binding experiments and affinity chromatography on immobilized thrombin-activated NDSK suggest that the changes in anticoagulant activity are not due to a proteolytic change in the carboxyl-terminal part of the γ-chain in the D moiety of the molecule. Our data suggest a correlation with the stage of digestion of the Aa-chain in the X-like fragments.

Keywords

Fibrinogen degradation product - Elastase - Calcium binding - Anticlotting properties
 

  • References

  • 1 Egbring R, Schmidt W, Fuchs G, Havemann K. Demonstration of granulocytic protease in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood 1977; 49: 219-231
    PubMedGoogle Scholar
  • 2 Egbring R, Havemann K. Possible role of polymorphonuclear granulocytic proteases in blood coagulation. In: Neutral Proteases of Human Polymorphonuclear Leukocytes. Havemann K, Janoff A. (Eds) pp 442-455 Urban and Schwarzenberg Inc.; Baltimore - Munich: 1978
    Google Scholar
  • 3 Gropp C, Egbring R, Havemann K. Fibrinogen split products, antiproteases and granulocytic elastase in patients with lung cancer. Eur J Cancer 1980; 16: 679-685
    CrossrefPubMedGoogle Scholar
  • 4 Plow EF, Edgington TS. The fibrinolytic pathway of leukocytes. In: Neutral Proteases of Human Polymorphonuclear Leukocytes. Havemann K, Janoff A. (Eds) pp 330-345 Urban and Schwarzenberg Inc.; Baltimore - Munich: 1978
    Google Scholar
  • 5 Gramse M, Bingenheimer C, Schmidt W, Egbring R, Havemann K. Degradation products of fibrinogen by elastase-like neutral protease from human granulocytes. Characterization and effects on blood coagulation in vitro J Clin Invest 1978; 61: 1027-1033
    CrossrefPubMedGoogle Scholar
  • 6 Gramse M, Bingenheimer C, Havemann K. Degradation of human fibrinogen by chymotrypsin-like neutral protease from human granulocytes. Thromb Res 1980; 19: 201-209
    CrossrefPubMedGoogle Scholar
  • 7 Gramse M, Bingenheimer C, Havemann K. Granulocytic elastase and its interference with fibrinogen. In: Neutral proteases of human polymorphonuclear leukocytes. Havemann K, Janoff A. (Eds) pp 347-355 Urban and Schwarzenberg Inc.; Baltimore - Munich: 1978
    Google Scholar
  • 8 Bingenheimer C, Gramse M, Egbring R, Havemann K. Fibrinogen degradation by two neutral granulocyte proteinases. Influence of calcium on the generation of fibrinogen degradation products with anticlotting properties Hoppe-Seyler’s Z physiol Chem 1981; 362: 853-861
    PubMedGoogle Scholar
  • 9 Sterrenberg L, Blonk A, van Liempt GJ, Hermans J, Nieuwenhuizen W. Purification and properties of early (X-like) and late (D-like) fibrinogen fragments produced by leukocyte elastase. In: Fibrinogen - Structure functional aspects metabolism. Haverkate F, Henschen A, Nieuwenhuizen W, Straub PW. (Eds) Walter de Gruyter & Co; Berlin/New York: 1983. 2 236-253
    Google Scholar
  • 10 van Ruijven-Vermeer IA M, Nieuwenhuizen W. Purification of rat fibrinogen and its constituent chains. Biochem J 1978; 169: 653-658
    CrossrefPubMedGoogle Scholar
  • 11 Blombäck B, Blombäck M, Henschen A, Hessel B, Iwanaga S, Woods KR. N-terminal disulphide knot of human fibrinogen. Nature 1968; 218: 130-134
    CrossrefPubMedGoogle Scholar
  • 12 Doolittle RF, Cassman KG, Cottrell BA, Friezner SJ, Bucko JT, Takagi T. Amino acid sequence studies on the α-chain of human fibrinogen. Characterization of 11 cyanogen bromide fragments Biochem 1976; 16: 1703-1709
    PubMedGoogle Scholar
  • 13 Baugh RJ, Travis J. Human leukocyte granula elastase: rapid isolation and characterization. Biochem 1976; 15: 836-841
    CrossrefPubMedGoogle Scholar
  • 14 Menninger H, Kruze D, Fehr K, Böni A. Neutrale Proteasen menschlicher Leukozytengranula. Verh Dtsch Ges Rheumatol 1978; 5: 200-203
    PubMedGoogle Scholar
  • 15 Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulphate-polyacrylamide gel electrophoresis. J Biol Chem 1969; 244: 4406-4412
    PubMedGoogle Scholar
  • 16 Zaccharius RM, Zell TE, Morrison JM, Woodlock JJ. Glycoprotein staining following electrophoresis on acrylamide gels. Anal Biochem 1969; 30: 148-152
    CrossrefPubMedGoogle Scholar
  • 17 Howe JG, Hershey JW B. A sensitive immunoblotting method for measuring protein synthesis initiation factor levels in lysates of Escherichia coli. J Biol Chem 1981; 256: 12836-12839
    PubMedGoogle Scholar
  • 18 Ouchterlony O. Diffusion-in-gel methods for immunological analysis. In: Progress in Allergy. Kallos P. (Ed) Karger; Basel: 1958. 5 1-78
    Google Scholar
  • 19 Grabar P. The immunoelectrophoretic method of analysis. In: Immunoelectrophoretic Analysis. Grabar P, Burtin P. (Eds) pp 3-30 Elsevier; Amsterdam: 1964
    Google Scholar
  • 20 Gray WR. Dansyl chloride procedure. Methods Enzymol 1967; 11: 139-151
    PubMedGoogle Scholar
  • 21 Nieuwenhuizen W, Vermond A, Nooijen WJ, Haverkate F. Calcium binding properties of human fibrin(ogen) and degradation products. FEBS Letters 1979; 98: 257-259
    CrossrefPubMedGoogle Scholar
  • 22 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement in the Folin reagent. J Biol Chem 1951; 193: 265-275
    PubMedGoogle Scholar
  • 23 Lawrie JS, Ross J, Kemp GD. Purification of firbrinogen and the separation of its degradation products in the presence of calcium ions. Biochem Soc Transact 1979; 7: 693-694
    CrossrefPubMedGoogle Scholar
  • 24 Sterrenberg L, Nieuwenhuizen W, Hermans J. Purification and characterization of a D-like fragment from human fibrinogen produced by human leukocyte elastase. Biochim Biophys Acta 1983; 775: 300-306
    PubMedGoogle Scholar
  • 25 Nieuwenhuizen W, Gravesen M. Anticoagulant activity and calciumbinding properties of high molecular weight derivatives of human fibrinogen, produced by plasmin (fragments X). Biochim Biophys Acta 1981; 668: 81-88
    CrossrefPubMedGoogle Scholar
  • 26 Nieuwenhuizen W, Haverkate F. Calcium-binding regions in fibrinogen. Ann N Y Acad Sci 1983; 408: 92-96
    CrossrefPubMedGoogle Scholar
  • 27 Niewiarowski S, Kowalski E. Un nouvel anticoagulant dérivé du fibrinogène. Rev Hématologie 1958; 13: 320-328
    PubMedGoogle Scholar
  • 28 Triantaphyllopoulos DC. Anticoagulant effect of incubated fibrinogen. Can J Biochem 1958; 36: 249-259
    PubMedGoogle Scholar
  • 29 Marder VJ, Shulman NR. High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. J Biol Chem 1969; 244: 2120-2121
    PubMedGoogle Scholar
  • 30 Dray-Attali L, Larrieu MJ. Fragments D-correlation between structure and biological activity. Thromb Res 1977; 10: 575-586
    CrossrefPubMedGoogle Scholar
  • 31 Haverkate F, Timan G, Nieuwenhuizen W. Anticlotting properties of fragments D from human fibrinogen and fibrin. Eur J Clin Invest 1979; 9: 253-255
    CrossrefPubMedGoogle Scholar
  • 32 Nieuwenhuizen W, Voskuilen M, Hermans J. Anticoagulant and calcium-binding properties of high molecular weight derivatives of human fibrinogen (plasmin fragments Y). Biochim Biophys Acta 1982; 708: 313-316
    CrossrefPubMedGoogle Scholar
  • 33 Nieuwenhuizen W, Voskuilen M, Vermond A, Haverkate F, Hermans J. A fibrinogen fragment D (D intermediate) with calcium-binding but without anticlotting properties. Biochim Biophys Acta 1982; 707: 190-192
    CrossrefPubMedGoogle Scholar
  • 34 Olexa SA, Budzynski AZ. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci 1980; 77: 1374-1378
    CrossrefPubMedGoogle Scholar
  • 35 Laudano AP, Doolittle RF. Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers. Proc Natl Acad Sci 1978; 75: 3085-3089
    CrossrefPubMedGoogle Scholar
  • 36 Doolittle RF. Structural aspects of the fibrinogen to fibrin conversion. Adv Prot Chem 1973; 27: 1-109
    PubMedGoogle Scholar
  • 37 Shen L, McDonagh RP, Hermans J. Early events in the plasmin digestion of fibrinogen and fibrin. Effects of plasmin on fibrin polymerization J Biol Chem 1977; 252: 6184-6189
    PubMedGoogle Scholar